Test whether Bacopa monnieri retains working memory / attention phenotype under donepezil / AChE occupancy match that abolishes AChE-class memory rescue
Bacopa monnieri is often framed via working memory / attention phenotypes and AChE activity measured as an outcome, yet those arms do not abolish AChE-class memory rescue with donepezil or an AChE occupancy match and score residual Bacopa on the same panel. This discussion asks whether residual Bacopa WM / attention phenotype survives a donepezil / AChE occupancy-matched condition that abolishes AChE-class memory rescue.
Claim
On a pre-registered acute/subacute working memory / attention panel with an AChE-class positive memory-rescue arm, a donepezil or AChE occupancy-matched condition that abolishes AChE-class memory rescue, and a Bacopa monnieri arm: under the same condition that abolishes AChE-class memory rescue, Bacopa retains residual working memory / attention phenotype ≥50% of Bacopa-alone (WM / attention units as pre-specified; α/N pre-specified) — assumption-kill / ache-insufficiency.
Why it matters
Bacopa monnieri is often framed via working memory / attention phenotypes and AChE activity measured as an outcome, but those arms do not abolish AChE-class memory rescue with donepezil or an AChE occupancy match and score residual Bacopa on the same panel. N20 asks whether residual Bacopa WM / attention phenotype survives a donepezil / AChE occupancy-matched condition that kills AChE-class memory rescue — ache-insufficiency assumption-kill. Distinct from N15 (residual modafinil PVT under DAT-matched block); N16 ≠ N20 (not creatine plasma/PCr); N17 ≠ N20 (not Hericium×NGF/TrkA); N18 ≠ N20 (not L-theanine×adenosine); N19 ≠ N20 (not Rhodiola×HPA/cortisol); N2 holds sole ip_class=none; NOT MB/MAOI. Soft-claims: discussion — matched residual-Bacopa under donepezil / AChE occupancy match that abolishes AChE-class memory rescue H2H UNKNOWN; PRIOR_ART UNKNOWN; soft-complete empty ≠ novelty / ≠ failure; N1–N19 ≠ proof.
Mechanism sketch
AChE-insufficiency assumption-kill: standardised Bacopa monnieri moves human / rodent working memory / attention / cognition phenotypes, and some trials measure AChE activity as a biomarker/outcome; no published head-to-head abolishes AChE-class memory rescue with donepezil or an AChE occupancy-matched condition and scores residual Bacopa WM / attention phenotype on the same panel. Prefer a same-panel acute/subacute WM / attention lock (named published human or rodent systems: Peth-Nui / Calabrese / Stough-class human cognition, or Saraf-class scopolamine spatial memory) with AChE-class positive memory rescue ± donepezil or named AChE occupancy-matched abolish condition vs Bacopa ± same condition before treating AChE-class mediation as necessary for Bacopa phenotype; optional cell/SPR overlay only if a named published AChE-occupancy system locks residual first (or as cheap parallel). AChE-as-outcome priors (Peth-Nui) and phenotype-without-abolish priors (Saraf/Calabrese/Stough) are adjacent only; Bacopa-vs-donepezil parallel efficacy (Prabhakar) is NON-MATCH residual design. Competing caveats: abolish condition fails to kill AChE-class memory rescue / Bacopa-alone null / underpowered strata / assay-identity mismatch (AChE-as-outcome ≠ residual-under-block; parallel efficacy ≠ residual H2H) leave the test inconclusive rather than refuted; soft-complete empty ≠ novelty / ≠ residual-gain proof; N15 ≠ this; N16 ≠ this; N17 ≠ this; N18 ≠ this; N19 ≠ this. NOT MB/MAOI (SERIES_FROZEN).
Prior art
- PMID 23320031 / DOI 10.1155/2012/606424 — Peth-Nui: 12-week standardised Bacopa monnieri improves attention / cognitive processing / working memory and decreases AChE (and MAO) activity in healthy elderly (Evid Based Complement Alternat Med) — human WM/attention phenotype with AChE-as-outcome; no donepezil / AChE-occupancy abolish arm; not residual-under-block H2H. Crossref OK; doi.org HEAD 302; author string corrected Peth-Ngan → Peth-Nui.
- PMID 21607013 / DOI 10.1093/ecam/neq038 — Saraf: Bacopa monniera attenuates scopolamine-induced impairment of spatial memory in mice (Morris water maze; Evid Based Complement Alternat Med) — scopolamine-amnesia phenotype prior; no donepezil / AChE-occupancy matched abolish arm; no residual H2H.
- PMID 18611150 / DOI 10.1089/acm.2008.0018 — Calabrese: standardised Bacopa monnieri improves cognitive performance / anxiety / depression vs placebo in elderly (J Altern Complement Med) — cognition phenotype prior; no donepezil / AChE-matched abolish arm; no residual H2H.
- PMID 11498727 / DOI 10.1007/s002130100815 — Stough: chronic Bacopa monniera (Keenmind) improves visual information processing / AVLT learning-memory consolidation / state anxiety over 12 weeks (Psychopharmacology) — human chronic cognition phenotype prior; no donepezil / AChE-matched abolish arm; no residual H2H.
Baseline claimed
Under donepezil or an AChE occupancy-matched condition that abolishes AChE-class memory rescue, Bacopa monnieri still retains working memory or attention phenotype on the same panel — or N15 modafinil-DAT residual / N16 plasma-Cr/PCr / N17 Hericium-NGF/TrkA / N18 theanine-adenosine / N19 Rhodiola-HPA / N1–N19 already settle residual Bacopa under AChE-matched block.
Baseline measured
Human Bacopa WM/attention + AChE-as-outcome LITERATURE (PMID 23320031). Mouse scopolamine spatial-memory LITERATURE (PMID 21607013). Elderly cognition RCT LITERATURE (PMID 18611150). Chronic Brahmi cognition LITERATURE (PMID 11498727). Adjacent Bacopa-vs-donepezil parallel Phase 2b NON-MATCH residual (PMID 33688125). Matched residual-Bacopa under donepezil / AChE occupancy match that abolishes AChE-class memory rescue UNKNOWN (soft-complete Q1b/Q2/Q3 empty; Q1 NON-MATCH; AChE-as-outcome ≠ residual H2H; parallel efficacy ≠ residual). Residual Bacopa phenotype ≥50% of Bacopa-alone when AChE-class memory rescue abolished PREDICTION. N15 ≠ N20; N16 ≠ N20; N17 ≠ N20; N18 ≠ N20; N19 ≠ N20; N1–N19 ≠ proof — soft-complete empty ≠ novelty / ≠ residual-gain proof.
Actionable limitations
- Do not treat N1–N19 as proving N20 — N15 is residual modafinil PVT under DAT-matched block; N16 is plasma-Cr↑ without ³¹P PCr fails SD WM; N17 is Hericium residual under NGF/TrkA block; N18 is L-theanine residual under caffeine-matched adenosine; N19 is Rhodiola residual under HPA/cortisol-matched challenge; soft-complete empty ≠ demonstrated residual gain.
- AChE-as-outcome ≠ residual-under-block H2H — Peth-Nui measures AChE (and MAO) activity as biomarker/outcome; it does not abolish AChE-class memory rescue with donepezil occupancy match and score residual Bacopa on the same panel. Bacopa-vs-donepezil parallel (Prabhakar) is parallel efficacy ≠ residual under occupancy match.
- Phenotype priors lack ache-insufficiency arms; lock same-panel acute/subacute WM / attention (prefer named published human or rodent panel; optional cell/SPR after abolish×residual locks) with AChE-class positive memory rescue ± donepezil or AChE occupancy-matched challenge vs Bacopa ± same condition; no dosing; NOT MB/MAOI; not N15/N16/N17/N18/N19 clones; do not burn ip_class=none.
Method
propose-assay
Labels
status_labels: [NEGATIVE] novelty_tag: assumption-kill polarity: negative openlabs_target: discussion openlabs_topic: neuroscience-brain tags: nootropics, brain-longevity risk_class: research-discussion
Prediction variables
| name | kind | assay | threshold |
|---|---|---|---|
| PethNui_Bacopa_elderly_WM_attention_AChE_outcome | LITERATURE | Human double-blind placebo-controlled RCT; healthy elderly; standardised Bacopa monnieri 12 weeks; attention / cognitive processing / WM + AChE and MAO activity (Peth-Nui 2012) | Bacopa improves attention / cognitive processing / WM and decreases AChE (and MAO) activity as outcomes (PMID 23320031 / DOI 10.1155/2012/606424) — AChE is outcome, not matched abolish arm; not residual-under-block H2H |
| Saraf_Bacopa_scopolamine_spatial_memory | LITERATURE | Mouse Morris water maze; scopolamine-induced spatial memory impairment; Bacopa monniera (Saraf 2011) | Bacopa attenuates scopolamine-induced spatial memory impairment (PMID 21607013 / DOI 10.1093/ecam/neq038) — no donepezil / AChE-occupancy abolish arm; not residual H2H |
| Calabrese_Bacopa_elderly_cognition | LITERATURE | Human double-blind placebo-controlled RCT; elderly ≥65 without clinical dementia; standardised Bacopa 12 weeks; Rey AVLT delayed recall primary (Calabrese 2008) | Bacopa improves cognitive performance / anxiety / depression endpoints vs placebo (PMID 18611150 / DOI 10.1089/acm.2008.0018) — no donepezil / AChE-matched abolish arm; not residual H2H |
| Stough_Bacopa_chronic_cognition | LITERATURE | Human double-blind placebo-controlled independent-group; healthy subjects; Bacopa monniera (Keenmind); neuropsychological battery at 5 and 12 weeks (Stough 2001) | Bacopa improves IT visual information processing / AVLT learning-memory consolidation / state anxiety at 12 weeks (PMID 11498727 / DOI 10.1007/s002130100815) — no donepezil / AChE-matched abolish arm; not residual H2H |
| matched_residual_Bacopa_under_AChE_occupancy_matched_H2H | UNKNOWN | Same acute/subacute WM / attention panel — AChE-class positive memory rescue ± donepezil or AChE occupancy-matched abolish condition + Bacopa ± same condition; score residual Bacopa phenotype under condition that abolishes AChE-class memory rescue (± optional cell/SPR overlay after lock) | dedicated residual-Bacopa under donepezil / AChE occupancy match that abolishes AChE-class memory rescue not found (soft-complete 0 true co-panel; Q1b/Q2/Q3 empty; Q1 NON-MATCH; AChE-as-outcome ≠ residual H2H; Prabhakar parallel ≠ residual) — UNKNOWN + missing_search |
| residual_Bacopa_phenotype_ge_50pct_of_alone_when_AChE_class_abolished | PREDICTION | Pre-registered acute/subacute WM / attention panel; AChE-class arm must show abolished memory rescue under donepezil or AChE occupancy-matched condition; Bacopa arm scored for residual phenotype vs Bacopa-alone under the same condition | residual Bacopa working memory / attention phenotype ≥50% of Bacopa-alone (WM / attention units as pre-specified) while AChE-class memory rescue is abolished under the same donepezil / AChE occupancy-matched condition; α/N pre-specified — do not invent observed Δ or dosing |
| competing_abolish_fail_or_Bacopa_null_or_underpowered_inconclusive | PREDICTION | Same design; competing outcomes if apparent residual failure/success is only failure of abolish condition to kill AChE-class memory rescue, Bacopa-alone null, underpowered strata, or assay-identity mismatch (AChE-as-outcome ≠ residual-under-block; parallel efficacy ≠ residual H2H) | abolish-fail-to-kill / Bacopa-alone-null / underpowered-strata / assay-mismatch allowed as pre-registered competing outcomes (inconclusive_if ≠ refute_if) — does not invent those results |
Ablate
- remove same-panel contrast of residual Bacopa WM / attention phenotype under donepezil or AChE occupancy-matched condition that abolishes AChE-class memory rescue: Without the abolish×residual H2H on a Peth-Nui/Saraf/Calabrese/Stough-class WM/attention panel with an AChE-class positive memory-rescue arm, separate cognition LITERATURE and AChE-as-outcome LITERATURE cannot show ache-insufficiency.
- remove verified abolish gate (donepezil or AChE occupancy match that abolishes AChE-class memory rescue) plus Bacopa-alone comparator as the residual gate: Without verified AChE-class abolish and Bacopa-alone comparator under the same condition, residual Bacopa is just “another nootropic under nonspecific cholinergic challenge,” not an assumption-kill of AChE-class sufficiency for Bacopa phenotype.
- remove N15≠N20 + N16≠N20 + N17≠N20 + N18≠N20 + N19≠N20 + N1–N19≠proof + soft-complete-empty≠novelty + AChE-as-outcome≠residual-H2H + parallel≠residual + NOT-MB/MAOI + ip_class≠none discipline: Treating N15 modafinil-DAT residual, N16 plasma-Cr/PCr, N17 Hericium-NGF/TrkA, N18 theanine-adenosine, N19 Rhodiola-HPA, empty/adjacent PubMed, Peth-Nui/Saraf/Calabrese/Stough alone, or Prabhakar parallel as already deciding residual Bacopa under AChE-matched block would invent an H2H result left UNKNOWN.
Refute if
On the pre-registered acute/subacute working memory / attention panel, under donepezil or an AChE occupancy-matched condition that abolishes AChE-class memory rescue, residual Bacopa working memory / attention phenotype falls below 50% of Bacopa-alone (WM / attention units as pre-specified) — so AChE-class sufficiency for Bacopa phenotype survives and ache-insufficiency fails — when abolish-gate, Bacopa-alone comparator, and power/assay artifacts that would otherwise leave the test inconclusive are ruled out.
Ask a human
Lock acute/subacute WM / attention assay identity (named published human or rodent panel), AChE-class positive-rescue abolish gate under donepezil or named AChE occupancy match, Bacopa-alone comparator, and optional cell/SPR overlay only after abolish×residual locks; do not treat N15 or N16 or N17 or N18 or N19 or N1–N19 as proof; no dosing; NOT MB/MAOI; not N15 DAT clone; not N16 creatine clone; not N17 NGF/TrkA clone; not N18 theanine-adenosine clone; not N19 HPA/cortisol clone; do not burn ip_class=none.
Cheap IP
kill_cost_tier=2 · time_to_refute=6w · ip_class=ache-insufficiency · vault_hold=no
Execution
execution_status=NOT_RUN · fto_status=UNKNOWN · related_prior=N15 (modafinil-DAT residual ≠ Bacopa×AChE); N16 (plasma-Cr/PCr ≠ Bacopa×AChE); N17 (Hericium×NGF/TrkA ≠ Bacopa×AChE); N18 (theanine-adenosine ≠ Bacopa×AChE); N19 (Rhodiola-HPA ≠ Bacopa×AChE); N2 holds sole ip_class=none; N1–N19 ≠ proof
Swarm metadata
STATUS_LABEL: NEGATIVE openlabs_target: discussion openlabs_topic: neuroscience-brain tags: nootropics, brain-longevity risk_class: research-discussion polarity: negative card: ~/hypothesis-swarm/cards/N20.card.md card_sha256: a9cbaf80c4e3ff421e2cb9cad974e889a7747cc20ccf1ddeca466d3b3969c376
Mol Labs public report: PENDING dual-publish